share_log

Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

Nautilus Biotechnology Reports Third Quarter 2024 Financial Results

鸚鵡螺體育報告2024年第三季度財務業績
Nautilus Biotechnology ·  10/29 12:00

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024.

2024年10月29日,西雅圖(GLOBE NEWSWIRE)-鸚鵡螺生物技術公司(納斯達克:NAUT;或「鸚鵡螺」),一家開創性的單分子蛋白質組分析平台公司,今日報告了截至2024年9月30日第三季度的財務業績。

"I'm excited about the expanding opportunity I see for proteomics and am pleased with the progress we're making as a business," said Sujal Patel, CEO of Nautilus. "We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what's currently available. It is becoming ever more apparent that they understand how important the single-molecule, intact protein analysis to be enabled by the Nautilus platform will be to their explorations of the proteome."

「我對蛋白質組學領域不斷擴展的機遇感到興奮,並對我們作爲一家業務所取得的進展感到滿意,」鸚鵡螺首席執行官蘇傑爾·帕特爾表示。「我們不斷收到來自世界各地研究人員的積極反饋,他們告訴我們他們渴望更深入、更廣泛地探索蛋白質組,以及目前可用資源的重大侷限性。他們越來越明白,通過鸚鵡螺平台實現的單分子完整蛋白質分析對於他們對蛋白質組的探索將會有多麼重要。」

Third Quarter 2024 Financial Results

2024年第三季度財務結果

Operating expenses were $19.1 million for the third quarter of 2024, flat compared to the corresponding prior year period. Overall personnel cost increased during the third quarter of 2024 as compared to the corresponding prior year period offset by a one-time reduction to accrued incentive compensation in the third quarter of 2024.

第三季度營業費用爲1910萬美元,與對應的上年同期持平。儘管2024年第三季度整體人員成本與對應的上年同期相比有所增加,但在2024年第三季度通過對應的上年同期的應計激勵補償一次性減少的抵消下。

Net loss was $16.4 million for the third quarter of 2024, as compared to a net loss of $15.9 million for the corresponding prior year period.

2024年第三季度淨損失爲1640萬美元,而去年同期淨損失爲1590萬美元。

Cash, cash equivalents, and investments were $221.2 million as of September 30, 2024.

截至2024年9月30日,現金、現金等價物和投資額爲22120萬美元。

Webcast and Conference Call Information

網絡廣播和電話會議信息

Nautilus will host a conference call to discuss the third quarter 2024 financial results, business developments and outlook before market open on Tuesday, October 29, 2024, at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: .

鸚鵡螺體育將於2024年10月29日星期二美國太平洋時間上午5:30 / 東部時間上午8:30,在市場開盤前舉行電話會議,討論2024年第三季度的財務狀況、業務發展和展望。網絡直播的現場音頻將在公司網站的"投資者"部分提供: .

About Nautilus Biotechnology, Inc.

關於Nautilus Biotechnology,Inc。

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit

Nautilus位於華盛頓州西雅圖市的公司總部和位於加利福尼亞州San Carlos的研究和開發總部,是一家開發階段的生命科學公司,致力於創建平台技術以量化和解鎖蛋白質組的複雜性。 鸚鵡螺體育的使命是通過民主化蛋白質組的獲取,並促進在人類健康和醫學方面的基本進展,從而改變蛋白質組學領域。 要了解更多關於鸚鵡螺體育,請訪問

Special Note Regarding Forward-Looking Statements

關於前瞻性聲明的特別說明

This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus' expectations regarding the company's business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the development required for and the timing of the launch of Nautilus' product platform and full commercial availability, the functionality and performance of Nautilus' product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus' products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus' assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus' product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus' scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption "Risk Factors" in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2024 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

本新聞稿包含根據聯邦證券法的前瞻性聲明。本新聞稿中的前瞻性聲明包括但不限於關於鸚鵡螺公司業務運營、財務表現和營業成果的期望;關於任何營收時間或預測的期望;關於鸚鵡螺產品平台開發所需及上市時間的期望和全面商用可用性、鸚鵡螺產品平台的功能和性能、其在蛋白質組獲取、藥物開發和藥物發現方面的潛在影響、擴展研究視野和促進科學探索和發現、以及新興蛋白質組技術的現有和未來能力與限制。這些聲明基於關於鸚鵡螺產品、目標市場和其他當前和新興蛋白質組技術的諸多假設,涉及重大風險、不確定性和可能導致實際結果與這些前瞻性聲明所表達或暗示信息有實質性不同的其他因素。可能會影響鸚鵡螺假設的準確性及實現本新聞稿中所設定的前瞻性聲明能力的風險和不確定性(但不限於):鸚鵡螺產品平台尚未商業化並仍需進行重大科學和技術開發,這在本質上是具有挑戰性和難以預測的,特別是對於鸚鵡螺開發的高度新穎和複雜產品。即使我們的開發工作取得成功,我們的產品平台將需要在生命科學研究中驗證其功能和效用方面進行大量驗證。在鸚鵡螺科學和技術開發以及相關的產品驗證和商業化過程中,我們可能會因意外事件而經歷重大延遲。我們無法就開發、合作和商業化倡議的結果或相關時間表向任何人提供擔保或保證。有關鸚鵡螺及其開發工作面臨的其他風險和不確定性的更詳細描述,投資者應參考我們的年度報告第10-k表格中標題爲「風險因素」的信息,以及我們將爲截至2024年9月30日季度報告第10-Q表中的信息以及我們向SEC的其他備案。本新聞稿中的前瞻性聲明截至本新聞稿日期。除非適用法律另有規定,鸚鵡螺不承擔更新任何前瞻性聲明的義務。因此,您不應依賴這些前瞻性聲明作爲我們在本新聞稿日期之後任何日期觀點的代表。

Disclosure Information

披露信息

Nautilus uses filings with the Securities and Exchange Commission, its website (), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

鸚鵡螺體育使用提交給證券交易委員會的文件、其網站()、新聞稿、公開電話會議、公開網絡廣播和其社交媒體帳戶作爲披露重要非公開信息並遵守FD法規的手段。因此,鸚鵡螺體育鼓勵投資者、媒體和其他對鸚鵡螺體育感興趣的人士查閱其在這些位置公開的信息,因爲這些信息可能被視爲重要信息。

Media Contact
press@nautilus.bio

媒體聯繫人
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

投資者聯繫方式
investorrelations@nautilus.bio

Nautilus Biotechnology, Inc.
Condensed Consolidated Balance Sheets
As of September 30, 2024 and December 31, 2023 (Unaudited)

鸚鵡螺生物技術公司。
簡明合併資產負債表
截至2024年9月30日和2023年12月31日(未經審計)

(in thousands, except share and per share amounts) September 30, 2024 December 31, 2023
Assets
Current assets:
Cash and cash equivalents $ 4,409 $ 19,397
Short-term investments 136,200 154,021
Prepaid expenses and other current assets 3,596 3,419
Total current assets 144,205 176,837
Property and equipment, net 4,324 4,267
Operating lease right-of-use assets 29,377 32,634
Long-term investments 80,618 90,647
Other long-term assets 1,180 1,180
Total assets $ 259,704 $ 305,565
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 1,487 $ 1,639
Accrued expenses and other liabilities 3,216 3,945
Current portion of operating lease liabilities 3,959 3,538
Total current liabilities 8,662 9,122
Operating lease liabilities, net of current portion 27,608 31,090
Total liabilities 36,270 40,212
Stockholders' equity:
Preferred stock
Common stock 13 13
Additional paid-in capital 478,115 467,834
Accumulated other comprehensive income (loss) 731 (255)
Accumulated deficit (255,425) (202,239)
Total stockholders' equity 223,434 265,353
Total liabilities and stockholders' equity $ 259,704 $ 305,565
(以千爲單位,除每股數據外) 2024年9月30日 2023年12月31日
資產
流動資產:
現金及現金等價物 $ 4,409 $ 19,397
短期投資 136,200 154021
預付費用和其他流動資產 3,596 3,419
總流動資產 144,205 176,837
資產和設備,淨值 4,324 4,267
經營租賃權使用資產 29,377 32,634
所有基金類型投資 80,618 90647
其他長期資產 1,180 1,180
總資產 $ 259,704 $ 305,565
負債和股東權益
流動負債:
應付賬款 $ 1,487 $ 1,639
應計費用及其他負債 3,216 3,945
經營租賃負債流動部分 3,959 3,538
流動負債合計 8,662 9,122
經營租賃負債,淨值超過流動資產 27,608 31,090
負債合計 36,270 40,212
股東權益:
優先股
13 13
額外實收資本 478,115 467,834
累計其他綜合收益(虧損) 731 (255)
累積赤字 (255,425) (202,239)
股東權益合計 223,434 265,353
負債和股東權益合計 $ 259,704 $ 305,565

Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Operations
Three and Nine Months Ended September 30, 2024 and 2023 (Unaudited)

鸚鵡螺體育生物技術公司,
簡明合併利潤表
2024年和2023年9月30日結束的三個月和九個月(未經審計)

Three Months Ended September 30, Nine Months Ended September 30,
(in thousands, except share and per share data) 2024 2023 2024 2023
Operating expenses
Research and development $ 12,288 $ 11,996 $ 37,654 $ 34,785
General and administrative 6,812 7,079 23,842 21,366
Total operating expenses 19,100 19,075 61,496 56,151
Other income (expense)
Interest income 2,674 3,197 8,349 9,517
Other expense (20) (39) (17)
Total other income $ 2,654 $ 3,197 $ 8,310 $ 9,500
Net loss $ (16,446) $ (15,878) $ (53,186) $ (46,651)
Net loss per share attributable to common stockholders, basic and diluted $ (0.13) $ (0.13) $ (0.42) $ (0.37)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 125,452,572 124,933,837 125,302,440 124,896,975
截至9月30日的三個月 截至9月30日的九個月
(以千爲單位,除股份數和每股數據外) 2024 2023 2024 2023
營業費用
研發 $ 12,288 $ 11,996 $ 37,654 $ 34,785
ZSCALER, INC. 6,812 7,079 23,842 21,366
營業費用總計 19100 19,075 61,496 56,151
其他費用收益
利息收入 2,674 3,197 8,349 9,517
其他支出 (20) (39) (17)
總其他收入 $ 2,654 $ 3,197 $ 8,310 $ 9,500
淨虧損 $ (16,446) $ (15,878) $ (53,186) $ (46,651)
每股普通股股東淨虧損,基本與稀釋後 $ (0.13) $ (0.13) $ (0.42) $ (0.37)
加權平均股數,用於計算歸屬普通股股東的基本和稀釋淨虧損 125,452,572 124,933,837 125,302,440 124,896,975

Nautilus Biotechnology, Inc.
Condensed Consolidated Statements of Cash Flows
Nine Months Ended September 30, 2024 and 2023 (Unaudited)

鸚鵡螺科技公司
基本報表
2024年和2023年截至9月30日的九個月(未經審計)

Nine Months Ended September 30,
(in thousands) 2024 2023
Cash flows from operating activities
Net loss $ (53,186) $ (46,651)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense 9,577 9,064
Amortization of operating lease right-of-use assets 3,257 2,821
Depreciation 1,543 1,294
Amortization (accretion) of premium (discount) on securities, net (2,176) (2,040)
Changes in operating assets and liabilities:
Prepaid expenses and other assets (26) (878)
Accounts payable (35) 22
Accrued expenses and other liabilities (729) 757
Operating lease liabilities (3,061) (2,200)
Net cash used in operating activities (44,836) (37,811)
Cash flows from investing activities
Proceeds from maturities of securities 90,410 51,249
Purchases of securities (59,398) (51,895)
Purchases of property and equipment (1,868) (2,029)
Net cash provided by (used in) investing activities 29,144 (2,675)
Cash flows from financing activities
Proceeds from exercise of stock options 415 23
Proceeds from issuance of common stock under employee stock purchase plan 289 92
Net cash provided by financing activities 704 115
Net increase (decrease) in cash, cash equivalents and restricted cash (14,988) (40,371)
Cash, cash equivalents and restricted cash at beginning of period 20,399 115,477
Cash, cash equivalents and restricted cash at end of period $ 5,411 $ 75,106
截至9月30日的九個月
(以千爲單位) 2024 2023
經營活動現金流
淨虧損 $ (53,186) $ (46,651)
調整淨虧損爲經營活動使用的現金淨額
股票補償費用 9,577 9,064
運營租賃權利資產攤銷 3,257 2,821
折舊費用 1,543 1,294
證券贖回溢價(折價)的攤銷(計提)淨額 (2,176) (2,040)
經營性資產和負債變動:
預付款項和其他資產 (26) (878)
應付賬款 (35) 22
應計費用及其他負債 (729) 757
經營租賃負債 (3,061) (2,200)
經營活動使用的淨現金流量 (44,836) (37,811)
投資活動現金流量
證券到期收回款 90,410 56,223
證券購入款項 (59,398) (51,895)
購買固定資產 (1,868) (2,029)
投資活動產生的淨現金流量 29,144 (2,675)
籌資活動現金流量
行使股票期權所得 415 23
在員工股票購買計劃下發行普通股的收益 289 92
籌資活動產生的現金淨額 704 115
現金,現金等價物和受限現金淨增加(減少) (14,988) (40,371)
期初現金、現金等價物及受限制的現金餘額 20,399 115,477
期末現金、現金等價物及受限制的現金餘額 $ 5,411 $ 75,106

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論